Market Estimates on Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016 ​is a new market research publication announced by Reportstack. This report provides an overview of the Acute Respiratory Distress Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Acute Respiratory Distress Syndrome, complete with analysis by stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Respiratory Distress Syndrome and features dormant and discontinued projects.

To view the table of contents and know more details please visit Acute Respiratory Distress Syndrome - Pipeline Review, H2 2016

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
- The report reviews pipeline therapeutics for Acute Respiratory Distress Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report reviews key players involved Acute Respiratory Distress Syndrome therapeutics and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Acute Respiratory Distress Syndrome

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies Mentioned

Altor BioScience Corporation Athersys, Inc. Faron Pharmaceuticals Oy FirstString Research, Inc. GlaxoSmithKline Plc Global Blood Therapeutics, Inc. Hydra Biosciences, Inc. Phylogica Limited S-Evans Biosciences, Inc. Savara Inc. Silence Therapeutics Plc

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###